GLPG Galapagos NV

Important update to Galapagos’ invitation to its ordinary and extraordinary shareholders’ meetings

Important update to Galapagos’ invitation to its ordinary and extraordinary shareholders’ meetings

Mechelen, Belgium; 17 April 2020, 01.15 CET; regulated information – In light of the ongoing COVID-19 pandemic, Galapagos NV (Euronext & NASDAQ: GLPG) will hold its shareholders’ meetings behind closed doors, with shareholder participation in advance only.

Out of safety precautions against the COVID-19 pandemic, and in accordance with the Royal Decree No. 4 under special powers published on 9 April 2020, the physical presence of shareholders, proxyholders, holders of subscription rights or other persons otherwise entitled to attend the shareholders’ meeting will be prohibited at Galapagos’ annual (ordinary) and extraordinary shareholders’ meetings scheduled for Tuesday 28 April 2020 at 2:00 p.m. (CET).

Shareholders are kindly invited and strongly encouraged to vote prior to the meetings, either by voting form or by proxy.

Please note the following alternative arrangements for the meetings:

      (1)   Proxies can only be granted to the general counsel. An updated proxy form is available on our website, under the tab “Investors > Shareholder Information > Shareholders’ Meetings > Proxy form”.

             

            If a proxy has already been received on the date and time of this press release in which a different proxy holder is appointed, the votes or abstentions will still be taken into account if the proxy contains specific voting instructions, and without this other proxy holder having to be present at the meetings;

             

      (2)   Voting forms and proxies must reach Galapagos before or on or 24 April 2020 at midnight CET at the latest.

             

            An updated voting form is available on our website, under the tab “Investors > Shareholder Information > Shareholders’ Meetings > Voting form”. If a voting form has already been received on the date and time of this press release, the votes or abstentions will still be taken into account;

             

  1. Only written questions may be submitted and must reach Galapagos before or on or 24 April 2020 at midnight CET at the latest. Answers will be published on our website at the latest prior to the vote;

     
  2. Both meetings will be held at the offices of Van Halteren notaires - notarissen, de Lignestraat 13, 1000 Brussels, instead of Galapagos’ registered office.

             

It is strongly recommended to use e-mail () only for all communications regarding the shareholders’ meetings, as postal services may be disrupted due to the pandemic. Please also note that the above mentioned Royal Decree exempts us from keeping the (updated) documents pertaining to the meetings physically available at our registered office or providing them by post.

The above mentioned arrangements prevail over the arrangements with the same subject as described in the convening notice, published on our website on 27 March 2020. An updated attendance notification form, taking into account that only voting prior to the meetings is allowed, is available on our website, under the tab “Investors > Shareholder Information > Shareholders’ Meetings > Attendance notification form”.

An updated convening notice and other documents pertaining to the shareholders’ meetings, including all details regarding the meetings’ procedures, can be consulted on our website, at . The Investor Relations team contacts below can assist with completion of shareholder participation in advance of the meetings.

Galapagos would like to thank its shareholders for their support during this unprecendented situation. For a letter from our CEO addressing the COVID-19 pandemic and its impact on Galapagos, please visit .

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at .

Contact

Investors:

Elizabeth Goodwin

VP Investor Relations

Sofie Van Gijsel

Director Investor Relations

5

Media:

Carmen Vroonen

Senior Director Communications & Public Affairs

Evelyn Fox

Director Communications

9

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

Disclaimer

The contents of our website, including the annual report for the financial year 2019, and any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.



 

 

Attachment

EN
16/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galapagos NV

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Mathijs Geerts Danau
  • Wim Hoste
  • Wim Lewi
 PRESS RELEASE

Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors  

Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors   Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board Mechelen, Belgium; February 19, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Dr. Paulo Fontoura as Non-Executive Independent Director to its Board of Directors, effective February 9, 2026. “We are pleased to welcome Paulo to our Board,” said Jérôme Contamine, Chair of the Board of Galapagos. “His global leadership experience, deep understanding ...

 PRESS RELEASE

Galapagos verwelkomt Dr. Paulo Fontoura in haar Raad van Bestuur  

Galapagos verwelkomt Dr. Paulo Fontoura in haar Raad van Bestuur   Dr. Fontoura brengt uitgebreide ervaring in wereldwijd leiderschap, klinische ontwikkeling en operationele aansturing mee naar de Raad van Bestuur Mechelen, België; 19 februari 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag de benoeming aan, via coöptatie, van Dr. Paulo Fontoura als Niet-Uitvoerend Onafhankelijk Bestuurder in haar Raad van Bestuur, met ingang van 9 februari 2026. “We zijn verheugd Paulo te verwelkomen in onze Raad van Bestuur”, aldus Jérôme Contamine, Voorzitter van de Raad van ...

 PRESS RELEASE

Galapagos Receives Transparency Notification from Bank of America

Galapagos Receives Transparency Notification from Bank of America Mechelen, Belgium; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on February 11, 2026, from Bank of America Corporation. The notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 5% of Galapagos’ voting rights on February 9, 2026, including the threshold of 5% for equival...

 PRESS RELEASE

Galapagos ontvangt transparantieverklaring van Bank of America

Galapagos ontvangt transparantieverklaring van Bank of America Mechelen, België; 16 februari 2026, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een transparantieverklaring ontvangen van Bank of America. Overeenkomstig de Belgische transparantiewetgeving1 ontving Galapagos op 11 februari 2026 een transparantieverklaring van Bank of America Corporation. Daaruit blijkt dat Bank of America Corporation, als controlerende entiteit, op 9 februari 2026 de drempel van 5% van de stemrechten van Galapagos heeft overschreden, met inbegrip van de drempel van 5%...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch